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To identify the molecular determinants responsible for lidocaine blockade of muscle-
type nAChRs, we have studied the effects on this receptor of 2,6-dimethylaniline (DMA),
which resembles lidocaine’s hydrophobic moiety. Torpedo marmorata nAChRs were
microtransplanted to Xenopus oocytes and currents elicited by ACh (IACh), either alone
or co-applied with DMA, were recorded. DMA reversibly blocked IACh and, similarly
to lidocaine, exerted a closed-channel blockade, as evidenced by the enhancement
of IACh blockade when DMA was pre-applied before its co-application with ACh, and
hastened IACh decay. However, there were marked differences among its mechanisms
of nAChR inhibition and those mediated by either the entire lidocaine molecule or
diethylamine (DEA), a small amine resembling lidocaine’s hydrophilic moiety. Thereby,
the IC50 for DMA, estimated from the dose-inhibition curve, was in the millimolar range,
which is one order of magnitude higher than that for either DEA or lidocaine. Besides,
nAChR blockade by DMA was voltage-independent in contrast to the increase of IACh
inhibition at negative potentials caused by the more polar lidocaine or DEA molecules.
Accordingly, virtual docking assays of DMA on nAChRs showed that this molecule
binds predominantly at intersubunit crevices of the transmembrane-spanning domain,
but also at the extracellular domain. Furthermore, DMA interacted with residues inside
the channel pore, although only in the open-channel conformation. Interestingly, co-
application of ACh with DEA and DMA, at their IC50s, had additive inhibitory effects on
IACh and the extent of blockade was similar to that predicted by the allotopic model
of interaction, suggesting that DEA and DMA bind to nAChRs at different loci. These
results indicate that DMA mainly mimics the low potency and non-competitive actions
of lidocaine on nAChRs, as opposed to the high potency and voltage-dependent block
by lidocaine, which is emulated by the hydrophilic DEA. Furthermore, it is pointed out
that the hydrophobic (DMA) and hydrophilic (DEA) moieties of the lidocaine molecule act
differently on nAChRs and that their separate actions taken together account for most
of the inhibitory effects of the whole lidocaine molecule on nAChRs.
Keywords: 2,6-dimethylaniline, lidocaine, nicotinic acetylcholine receptors, Xenopus oocytes, microtransplanted
receptors, allosteric modulation
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INTRODUCTION
The nicotinic acetylcholine receptor (nAChR) is the prototypical
member of the ligand-gated ion channel (LGIC) superfamily.
This receptor mediates fast excitatory synaptic transmission in
both peripheral and central nervous systems and it is essential for
evoking skeletal muscle contraction (Albuquerque et al., 2009).
In the past few years, a growing number of ligands have been
developed to selectively modulate nAChRs, as potential tools for
the treatment of different pathophysiological processes, including
addiction, depression, cognitive alterations, motor dysfunctions,
inflammation, and pain (Taly et al., 2009; Hurst et al., 2013; Wu
et al., 2015), indicating that nAChRs constitute a chief therapeutic
target.
Nicotinic acetylcholine receptor function can be modulated by
a broad number of molecules, some of them containing tertiary-
amino or quaternary-ammonium groups in their structure,
including: (i) local anesthetics (LAs) like lidocaine (Alberola-
Die et al., 2011, 2013) or its structural analogs, QX-314 and
QX-222 (Neher and Steinbach, 1978; Pascual and Karlin, 1998);
(ii) cholinesterase inhibitors as BW284c51, edrophonium or
decamethonium (Olivera-Bravo et al., 2007) and (iii) small
molecules such as choline (Grosman and Auerbach, 2000;
Lape et al., 2009), TMA and TEA (Akk and Steinbach, 2003)
or DEA (Alberola-Die et al., 2016). All these molecules are
totally or partially protonated at physiological pH and, thus,
their quaternary-ammonium group might be responsible for
nAChR inhibition by open-channel blockade, acting within the
channel pore (Arias, 2006). However, several LAs, as adiphenine,
proadifen, or lidocaine exert multiple inhibitory actions on
nAChRs (Spitzmaul et al., 2009; Alberola-Die et al., 2011, 2013),
which cannot be solely explained by the interaction of an
ammonium group within the channel pore, because they also
enhanced desensitization and caused closed-channel blockade.
For these reasons, hydrophobic aromatic rings, which are present
in most LAs, are expected to play a relevant role.
In a previous work we have found that DEA, a structural
analogous of lidocaine’s hydrophilic moiety, mimics some,
but not all, of the modulating effects of the entire lidocaine
molecule on muscle-type nAChRs (Alberola-Die et al., 2016).
Consequently, the present study is aimed, first, to unravel the
effects of DMA, which resembles lidocaine’s hydrophobic ring
(see molecular structures in Figure 1A), on this receptor and to
decipher the nAChR loci at which DMA binds. The second goal is
to correlate the mechanisms of action of DMA on nAChRs with
those reported for either the entire lidocaine molecule (Alberola-
Die et al., 2011) or the hydrophilic moiety of lidocaine, DEA
Abbreviation: ACh, acetylcholine; ANR, normal Ringer solution with atropine;
BW284c51, 1,5-bis(4-allyldimethylammoniumphenyl)pentan-3-one dibromide;
DEA, diethylamine; DMA, 2,6-dimethylaniline; DMSO, dimethyl sulfoxide;
EC, extracellular; IACh, ACh-elicited current; IC, intracellular; LA, local
anesthetic; LGIC, ligand-gated ion channel; MS-222, ethyl 3-aminobenzoate
methanesulfonate; n, number of oocytes; N, number of oocyte-donor frogs;
nAChR, nicotinic acetylcholine receptor; NR, normal Ringer solution; QX-
222, 2-(trimethylammonio)-N-(2,6-dimethylphenyl) acetamide chloride;
QX-314, 2-(triethylammonio)-N-(2,6-dimethylphenyl) acetamide bromide;
TEA, tetraethylammonium; TM, transmembrane spanning-segment; TMA,
tetramethylammonium.
(Alberola-Die et al., 2016). Our results indicate that although
both DEA and DMA block nAChRs, their mechanisms of action
and binding sites on this receptor are markedly different.
Preliminary results have previously appeared in a conference
abstract (Alberola-Die et al., 2009).
MATERIALS AND METHODS
Purification and Reconstitution of
nAChRs
Nicotinic acetylcholine receptors from Torpedo marmorata
electroplax were purified by bromoacetylcholine-affinity
chromatography in the presence of asolectin lipids using cholate
as a detergent. After elution with carbamylcholine, purified
receptors were dialyzed and reconstituted in asolectin lipids at
a final protein concentration of 0.3–1.2 mg ml−1. Samples were
aliquoted and stored in liquid nitrogen (Ivorra et al., 2002).
Oocyte Preparation and Microinjection
Adult female Xenopus laevis (purchased from Harlan Interfauna
Ibérica S.L., Barcelona, Spain; and Centre National de la
Recherche Scientifique, Montpellier, France) were immersed in
cold 0.17% MS-222 for 20 min and a piece of ovary was drawn
out aseptically. Animal handling was carried out in accordance
with the guidelines for the care and use of experimental animals
adopted by the E.U. and the animal protocol was approved by
the Ethic Committee of Universidad de Alicante. Stage V and
VI oocytes were isolated and their surrounding layers removed
manually. Cells were kept at 15–16◦C in a modified Barth’s
solution [88 mM NaCl, 1 mM KCl, 2.40 mM NaHCO3, 0.33 mM
Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 10 mM HEPES
(pH 7.4), 100 U ml−1 penicillin and 0.1 mg ml−1 streptomycin]
until used. Oocytes were microinjected with 100 nl of an aliquot
of reconstituted nAChRs (Morales et al., 1995).
Two-Electrode Voltage-Clamp
Recordings in Oocytes
Membrane current recordings were performed at 21–25◦C, 16–
72 h after proteoliposome injection, using a high compliance
two-microelectrode voltage-clamp system (TurboTEC-10CD,
npi Tamm, Germany). The recording methodology has been
described previously (Morales et al., 1995; Alberola-Die et al.,
2016). Briefly, oocytes were placed in a 150 µl recording chamber
and continuously superfused with normal frog Ringer’s solution
(NR: 115 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 5 mM HEPES,
pH 7.0) supplemented with 0.5 µM atropine sulfate (ANR)
to block any muscarinic response (Kusano et al., 1982). The
membrane potential was held at −60 mV, unless otherwise
stated. ACh and other tested drugs were diluted in ANR solution
and oocytes were superfused with them at a flow rate of 13–
17 ml min−1. Membrane currents elicited by ACh (IACh) either
alone or co-applied with DMA, were low-pass filtered at 30–
1000 Hz and, after sampling at fivefold the filter frequency
(Digidata series 1200 and 1440A; Axon Instruments, Foster
City, CA, USA), recorded on two PC-computers, using the
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WCP v. 3.2.8 package developed by J. Dempster (Strathclyde
Electrophysiology Software, University of Strathclyde, Scotland,
UK) and AxoScope v. 10.0.0.60 (Molecular Devices Corporation,
Sunnyvale, CA, USA).
Experimental Design
Experimental procedures were similar to those used to study
the modulating effects of lidocaine (Alberola-Die et al., 2011)
and DEA (Alberola-Die et al., 2016) on nAChRs. Briefly, DMA
concentration-IACh inhibition relationship was determined by
measuring IAChs evoked by 10 µM ACh alone or together
with different DMA concentrations. For competition assays,
ACh concentration-IACh amplitude curves were obtained by
exposing injected oocytes to increasing ACh concentrations,
either alone or together with 2 mM DMA. IAChs were recorded
in the presence or absence of DMA, normalized to the IACh
evoked by 1 mM ACh alone, and the values fitted to a
sigmoid curve (see below Eq. (3)). To allow nAChRs to recover
from desensitization, the interval between consecutive ACh
applications was at least 5 min. To assess the blockade of resting
nAChRs by DMA, we compared the IAChs elicited by ACh (from
1 µM to 1 mM) alone or co-applied with 2 mM DMA either
directly or after pre-application of DMA (same concentration)
for 12 s.
The voltage dependence of the IACh blockade by DMA was
determined by applying to the oocyte series of 800 ms voltage
pulses (from −120 to +60 mV, in 20 mV steps) before ligand
superfusion and during the IACh plateau elicited by 10 µM ACh,
either alone or co-applied with DMA at different concentrations;
the−120 mV pulse duration was extended up to 1500 ms to allow
a more complete current relaxation.
Data Analysis and Statistical Procedures
Inhibition curves were determined by measuring IACh evoked by
10 µM ACh in the presence of different DMA concentrations.
IAChs elicited in the presence of DMA were normalized to the
IACh evoked by ACh alone. Data were fitted to a single-site
inhibition curve using the Origin 6.1 software (OriginLab, Corp.
Northampton, MA, USA).
Recovery from IACh blockade by DMA was determined by
giving 32 s pulses of ACh either alone or co-applied with DMA,
for solely the first 12 s or during the whole pulse; IACh recovery
was measured 20 s and 7 min after DMA washout. The percentage
of recovery from blockade (% Recovery) was obtained using the
Eq. (1):
% Recovery = IACh after DMA − IACh+DMA
IACh − IACh+DMA × 100
where IACh is the current amplitude evoked by 10 µM ACh alone;
IACh+DMA, is the current elicited by co-application of 10 µM
ACh with 2 mM DMA; and IACh after DMA is the current obtained
20 s or 7 min after DMA removal.
The rate of desensitization (IACh decay) was determined
by measuring the IACh amplitude elicited by 100 µM ACh,
either alone or co-applied with different concentrations of
DMA (100 µM–2 mM), at different times after IACh peak.
Desensitization rates were obtained using the Eq. (2):
Dti = [1− (Iti/Ipeak)] × 100
where Dti is the desensitization value at 2, 10, or 20 s after the
peak; Ipeak the IACh amplitude at the peak; and Iti the current
amplitudes remaining after the specified times (Olivera-Bravo
et al., 2007). The apparent time-to-peak was determined as the
time elapsed from IACh onset to the IACh peak, from currents
elicited by ACh either alone or with DMA. We have called
this parameter as “apparent” time-to-peak, just to indicate that
these values do not necessarily reflect “real” time-to-peak values
of nAChR activation but those observed in our experimental
conditions.
To characterize the pharmacological profile of DMA, nAChRs
were activated by different ACh concentrations either alone or
co-applied with DMA (at roughly its IC50, unless otherwise
stated), just directly or after its pre-application for 12 s. Dose-
response data were fitted to the following form of the Hill Eq. (3):
I/Imax = [1+ (EC50/[ACh])nH ]−1
where I is the IACh peak elicited at a given ACh concentration
([ACh]; applied either alone or together with DMA); Imax is
the maximum IACh recorded; EC50 is the agonist concentration
required to obtain one-half the maximum IACh; and nH is the Hill
coefficient.
Net i/v curves for IACh were obtained by subtracting, for each
voltage, the steady-state currents attained in ANR (measured
during the last 100 ms of the pulse) from the corresponding ones
recorded in presence of 10 µM ACh. These net IACh values were
normalized, for each oocyte, to the ACh response at−60 mV.
To explore whether DEA and DMA molecules bind at the
same loci of nAChRs, we applied both molecules, at their
corresponding IC50s, together with ACh, to assess if their co-
application causes additive inhibiting effects on IACh. The extent
of IACh inhibition was later compared to that predicted by
allotopic and syntopic models (Jarvis and Thompson, 2013). The
inhibition values for the allotopic model were computed with
Eq. (4):
InDEA,DMA = InDEA+ InDMA − InDEAInDMA
where InDEA,DMA is the predicted IACh inhibition when DEA and
DMA are co-applied; InDEA and InDMA are the IACh inhibitions
caused by DEA and DMA, respectively. The inhibition values for
the syntopic model were computed with Eq. (5):
InDEA,DMA = InDEA + InDMA−2InDEAInDMA1− InDEAInDMA
Unless otherwise specified, values given are the mean ± SEM;
“n” indicates the number of oocytes and “N” is the number
of oocyte-donor frogs from which data were obtained. When
comparing two-group means of normally distributed values, the
Student’s t-test was used; otherwise, Mann-Whitney rank-sum
test was applied. Among-group differences were determined by
the analysis of variance (ANOVA) and mean differences for
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each pair of groups were determined with the Bonferroni t-test.
The one-sample t-test was used to compare the mean of an
experimental group with a specified value. For the comparison of
IC50 or EC50 values we used the confidence intervals computed
by the curve-fitting function of Origin 6.1 software, using
a percentage of confidence of 95%. The criterion of “non-
overlapping 95% confidence intervals” was used to determine
significant difference between EC50s. A significance level of
p< 0.05 was considered for all cases.
Virtual Docking Assays
Docking assays were carried out as previously described
(Alberola-Die et al., 2016). Briefly, Torpedo nAChR structures
in the closed (4 Å resolution, code 2BG9; Unwin, 2005) and
open (6.2 Å resolution, code 4AQ9; Unwin and Fujiyoshi,
2012), were taken from RCSB Protein Data Bank. The edition
of the protein was made using DeepView v4.1 (Guex and
Peitsch, 1997) and Yasara (Krieger et al., 2002, 2004) software
without further optimization. DMA, lidocaine and propofol
structures (CIDs, 6896, 3676, and 4943, respectively) were taken
from NCBI Pubchem database1. A global docking procedure
was accomplished with AutoDock 4 (Morris et al., 2008)
implemented in Yasara, where a total of 500 flexible docking runs
were set and clustered around the putative binding sites. The
program then performed a simulated annealing minimization
of the complexes, which moved the structure to a nearby stable
energy minimum, by using the implemented AMBER 99 force
field (Duan et al., 2003). The best binding energy complex in
each cluster was stored, analyzed and used to select the best
orientation of the interacting partners. Figures were drawn with
open source Pymol (The PyMOL Molecular Graphics System,
Version 1.8 Schrödinger, LLC2). Yasara pH command was set
to 7.0, ensuring that molecules preserve their pH dependency
of bond orders and protonation patterns. In this way, DMA
molecules remained during the docking procedure uncharged,
but 86% of the lidocaine molecules were protonated.
Drugs
Acetylcholine, atropine sulfate, DEA, DMA, DMSO, MS-222,
penicillin and streptomycin were from Sigma (St. Louis, MO,
USA). HEPES was obtained from Acros Organics (Morris
County, NJ, USA). Reagents of general use were purchased from
Scharlau Chemie SA (Barcelona, Spain). DMA solutions were
prepared from a 1M stock solution in DMSO. All solutions were
made in ANR just before each application.
RESULTS
Inhibition of IACh by DMA
Either in uninjected cells or in oocytes bearing nAChRs, with
the membrane potential held at −60 mV, DMA application
did not appreciably modify the cell membrane conductance
at concentrations lower than 5 mM, indicating both a lack
1http://www.ncbi.nlm.nih.gov/pccompound
2http://www.pymol.org/
of unspecific effect of DMA on native ion channels opened
at rest and that DMA did not act as a partial agonist of
nAChRs. Nevertheless, at higher DMA concentrations some
oocytes showed a slight decrease in their membrane conductance
(not shown), although we have not pursued the basis of this effect.
In oocytes that had incorporated nAChRs, co-application
of 10 µM ACh with DMA, at concentrations ranging from
100 µM to 50 mM, inhibited peak IACh amplitude in a
concentration-dependent manner (Figure 1). The half-inhibitory
DMA concentration (IC50), obtained by fitting the data to the Hill
equation, was 2.1 mM (confidence interval, 1.7–2.7 mM), and the
Hill coefficient (nH) 1.2± 0.2 (Figure 1C), indicating that a single
DMA molecule is sufficient to block the nAChR.
Nicotinic acetylcholine receptor blockade by DMA outlasted
the drug application, as also occurred for lidocaine and DEA
(Alberola-Die et al., 2011, 2016). Thereby, 20 s after rinsing out
DMA (2 mM), the percentage of IACh recovery (see Materials
and Methods, Eq. (1)) was only 52.0 ± 2.2% (Figures 2A,C),
increasing to 85.1 ± 5.1% when the elapsed time was 7 min
(Figures 2B,C). Thus, the IAChs after both DMA washout times
were significantly smaller than in control conditions, indicating a
slow nAChR recovery from blockade.
Open-Channel Blockade of nAChRs by
DMA
We measured IAChs at different membrane potentials by applying
voltage jumps (from−120 to+60 mV, in 20 mV steps) in absence
(not shown) or presence of 10 µM ACh applied either alone
or together with 2 mM DMA (Figure 3A) to determine if IACh
inhibition by DMA has any voltage-dependence, which would
suggest its binding into the channel pore.
The i/v curves of net IAChs (see Materials and Methods)
elicited by ACh either alone or co-applied with 2 mM DMA are
shown in Figure 3B. The presence of DMA did not affect the IACh
reversal potential, thus the channel ion selectivity was unaffected.
However, 2 mM DMA reduced IACh amplitude in a similar
percentage at all tested potentials (Figures 3A,B), indicating that
DMA caused a voltage-independent blockade of nAChRs. This
lack of voltage-dependence of IACh blockade by DMA is more
evident when plotting the percentage of IACh remaining after co-
applying ACh with DMA, normalized to its control IACh, against
membrane potential (Figure 3C). Notice that when measured at
the IACh plateau, the current left upon 2 mM DMA was roughly
30% of the control values at any potential tested (Figure 3C). This
percentage of IACh remaining is fairly smaller than that found
when considering the IACh peak (40–50%, Figure 1C) and this
discrepancy is most likely due to the enhancement of IACh decay
by DMA (see below).
Since DMA is a non-charged molecule, the lack of voltage-
dependence of nAChRs blockade by DMA does not fully exclude
that this molecule can bind into the channel pore. Therefore,
to ascertain if DMA actually binds into the channel pore we
analyzed the “rebound” currents elicited by ACh either alone
or in the presence of 2 mM DMA (Figure 4). It is well-
established that high doses of ACh elicit open-channel blockade
of nAChRs, evidenced by an IACh rebound just when rinsing
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FIGURE 1 | 2,6-Dimethylaniline (DMA) inhibits ACh-induced currents
(IAChs). (A) Molecular structures of lidocaine and DMA, showing the
resemblance of DMA to the phenolic ring of lidocaine. (B) Superimposed
IAChs, recorded in the same nAChR-bearing oocyte, by application of 10 µM
ACh either alone (Control) or together with DMA, at the indicated
concentrations. In this and following figures, unless otherwise stated, the
holding potential was −60 mV, downward deflections denote inward currents
and the horizontal bar above records corresponds to the timing of drug
application. (C) DMA concentration-IACh inhibition relationship. Amplitude of
the IAChs evoked in presence of DMA was normalized to the IACh elicited by
ACh alone (Control) and plotted as a function of the logarithm of the DMA
concentration. Solid line is a sigmoid curve fitted to the data and error bars are
SEM. Each point is the average of 4–28 oocytes from 3 to 13 frogs.
FIGURE 2 | Slow recovery from nAChR blockade by DMA.
(A) Superimposed IAChs evoked sequentially, in the same oocyte, by
superfusing the cell with 10 µM ACh alone [(1), black bar and recording],
co-applied with 2 mM DMA [(2), green bar and recording] or when changing
from ACh plus DMA to ACh alone at the time indicated by the bars [(3), green
followed by black bars and blue recording]. Note the incomplete recovery of
IACh amplitude after washing DMA for 20 s. (B) Superimposed currents
obtained by superfusing one oocyte with 10 µM ACh alone (Control, black
recording) or plus DMA (+ 2 mM DMA, green recording). Seven min after
DMA withdrawal (Postcontrol, gray recording), IACh did not fully reach the
control amplitude. (C) Column graph showing the percentages of IACh
recovery after 20 s or 7 min from DMA washout. Asterisks indicate significant
differences respect to the control response.
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FIGURE 3 | IACh blockade by DMA lacks of voltage dependence. (A)
Whole membrane currents (upper traces) evoked by applying to an oocyte the
voltage protocol shown on bottom, during the current plateau elicited by
10 µM ACh, either alone (black) or with 2 mM DMA (green). (B) Net i/v
relationships for IACh, obtained by applying the voltage protocol shown in (A)
while superfusing the cells with 10 µM ACh either alone (black filled circles) or
co-applied with 2 mM DMA (green open circles). Values represent the
percentage of current referred to their control IACh at -60 mV; each point is the
average of 5 cells (N = 3). (C) Plot showing the fraction of plateau IACh left by
2 mM DMA (IACh+DMA), normalized to its control (IACh), versus the membrane
potential. Same cells than in (B). Note the lack of a clear voltage dependence
of IACh blockade by DMA. The dashed red line shows the best linear fit to the
data; the fitted line has a correlation coefficient of −0.21, giving a p of 0.58
(the probability for the t-test of the slope = 0).
FIGURE 4 | IACh rebound elicited by DMA washout. When an oocyte was
challenged with a high ACh concentration (1 mM), while holding its membrane
potential at −60 mV (Vh = −60 mV), the IACh showed a marked
desensitization and a noticeable rebound-current (A2, black recording and
arrow) when the agonist was rinsed. By contrast, both when applying the
same ACh concentration to the cell at a membrane potential of +40 mV (A1,
black recording), or when decreasing the ACh concentration to 10 µM (B,
black recording), the IACh rebound was not evoked. However, when ACh was
co-applied with 2 mM DMA the IACh rebound was evident at any potential or
ACh concentration tested (A1,A2,B, green recordings and arrows).
out the agonist. This current arises during the agonist washout
because then the ACh leaves the channel, unplugging the pore,
when it can be still bound to the high affinity orthosteric sites
(Legendre et al., 2000; Liu et al., 2008). This open-channel
blockade of nAChRs by high ACh concentrations is only found
at negative membrane potentials, because at positive voltages
the positively charged ACh is electrostatically repelled from
the channel pore (compare control IAChs, black recordings, of
Figures 4A1,A2). However, when 1 mM ACh was co-applied
with 2 mM DMA, rebound currents were elicited both at positive
and negative potentials (Figures 4A1,A2, green traces), indicating
that the uncharged DMA is binding into the channel pore with
low affinity, and thereby eliciting an open-channel blockade of
nAChRs. Furthermore, this IACh rebound was also elicited when
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2 mM DMA was co-applied with a low ACh concentration
(10 µM) at negative potentials, in spite of the fact that ACh,
at this concentration, cannot block by its own the channel pore
(Figure 4B). Noticeably, when DMA concentration decreased
below 500 µM, this rebound currents were not elicited (see in
the recordings of Figure 1B that the rebound current appears at
2 mM DMA) and they were of larger amplitude when the cell was
challenged with a relatively high ACh concentration (100 µM or
higher; compare recordings of panels A2,B of Figure 4).
DMA Enhanced IACh Decay and
Decreased the Time-to-Peak
When either 10 or 100 µM ACh were co-applied with DMA,
at roughly its IC50, IACh decays were significantly accelerated
with respect to those evoked by ACh alone, suggesting an
enhancement of nAChR desensitization by DMA. Dti values at 2
and 20 s (see Eq. (2) in Materials and Methods) were: 36 ± 5%
and 92 ± 1%, for 100 µM ACh alone versus 50 ± 5% and
99 ± 1% for 100 µM ACh plus 2 mM DMA, respectively (same
cells in both groups; n = 18, N = 14; p < 0.05, ANOVA; see
Figures 5A,B). This effect was fully reverted 7 min after DMA
rinsing with ANR (40 ± 5% and 93 ± 2%; p > 0.05, ANOVA,
Figure 5B). Additionally, DMA diminished the apparent time-
to-peak, i.e., the time elapsed from IACh onset to IACh peak, from
1.6 ± 0.2 s for 100 µM ACh alone to 1.1 ± 0.2 s for 100 µM
ACh plus 2 mM DMA (same cells that IACh decay measurements;
p< 0.05, ANOVA; Figures 5A,C). Noteworthy, the time-to-peak
reverted to control values 7 min after DMA washout (1.6± 0.3 s;
see Postcontrol of Figures 5A,C), as the IACh decay rate did.
Interestingly, DMA hastening of IACh decay was dose-dependent,
starting the increase of desensitization at concentrations as low as
100 µM DMA (Figure 5D; p< 0.05, one sample t-test).
Since co-application of ACh with 2 mM DMA elicits rebound-
currents during the washout, suggesting that DMA can plug
the channel pore, the acceleration of IACh decay could be due
either to an enhancement of nAChR desensitization or to a slow
binding of DMA to the channel pore. In order to differentiate
between both mechanisms, we co-applied 2 mM DMA with
two different concentrations of ACh (10 µM and 1 mM) at
+40 mV (Figures 6A1,A2), because at this membrane potential
ACh does not contribute to the open-channel blockade. Co-
application of 10 µM ACh with 2 mM DMA inhibited IACh
by 50.0 ± 9.3% (n = 4; N = 3), as it would be expected
from the dose-inhibition curve (Figure 1C), and there was a
pronounced acceleration of IACh decay, which followed a single
exponential function (Figure 6A1, red discontinuous line), with
a time-constant (τ) of 3.34 ± 1.44 s (Figure 6B). When the
same concentration of DMA was co-applied with 1 mM ACh, the
IACh decreased by only 35.4 ± 4.3% (see Figures 6A2 and 7A1)
and the IACh decayed following a double exponential function
(Figure 6A2, red discontinuous line), with a τ value for the
fast component of 0.40 ± 0.05 s (Figure 6B). Given the large
differences in the τ values for the IACh decay caused by the same
DMA concentration when co-applied with two different ACh
concentrations, it follows that the acceleration of IACh decay by
DMA cannot only be explained by its binding into the channel
pore, acting as an open-channel blocker, but rather it points out
that DMA actually enhances nAChR desensitization.
Effects of DMA on nAChR
Pharmacological Profile
The pharmacological profile of nAChR inhibition by DMA was
studied by superfusing ACh at different concentrations (1, 3,
10, 100, and 1000 µM) alone or co-applied with 2 mM DMA
either directly (Figure 7A1) or after 12 s pre-application of the
same DMA concentration (Figure 7A2). Figure 7B shows the
relationship between ACh-concentration and IACh amplitude in
absence and presence of DMA. The sigmoid curve fitted for IAChs
elicited by ACh alone gave an EC50 of 29µM (confidence interval,
22–44 µM) and an nH of 2.0 ± 0. 1, which are similar values to
those previously reported for this receptor (Morales et al., 1995;
Alberola-Die et al., 2016). When 2 mM DMA was co-applied with
the different ACh concentrations, the IACh amplitude decreased,
even with the highest (almost saturating) ACh concentration
(Figures 7A1,B), suggesting a non-competitive blockade of
nAChRs by DMA. Furthermore, the dose-response curve shifted
to the right (Figure 7B), increasing significantly the EC50 up
to 63 µM (confidence interval, 50–96 µM) and decreasing the
slope to 1.3 ± 0.1. A similar reduction in the slope of the
ACh concentration-IACh amplitude relationship was found when
co-applying ACh with the quaternary-ammonium BW284c51
(Olivera-Bravo et al., 2005) or lidocaine (Alberola-Die et al.,
2011), though the mechanisms underlying this effect remains
unclear, since it is only partially dependent on the increase of
nAChR desensitization caused by these drugs (Alberola-Die et al.,
2011). Nonetheless, given that the percentage of IACh inhibition
was also dependent on ACh concentration, nAChR blockade
by DMA was not exclusively a non-competitive antagonism.
Thus, at low (10 µM) ACh concentration, 2 mM DMA blocked
roughly half the control IACh (Figures 7A1,B,C), as expected
from its estimated IC50 (see Figure 1). However, at very high ACh
concentration (1 mM), the percentage of IACh blockade decreased
significantly (Figures 7A1,B,C; p< 0.05, ANOVA). Although, we
cannot fully discard some competitive interactions of DMA and
ACh on the orthosteric binding sites (see below), this apparent
competitive mechanism of blockade could be explained by the
binding of DMA to the nAChR in its closed state, in a similar
way as we have previously proposed for lidocaine and also for
DEA (Alberola-Die et al., 2011, 2016). To test this hypothesis,
we determined the percentages of IACh blockade induced by
DMA (2 mM) when it was pre-applied to the oocyte for 12 s
before being co-applied with ACh at increasing concentrations
(1 µM–1 mM; Figures 7A2,B,C). As shown in panels 7A2,B, the
percentage of IACh remaining when ACh was co-applied with
2 mM DMA, after being pre-applied for 12 s, was significantly
reduced with 10 µM or higher ACh concentrations, as compared
with those corresponding to solely ACh and DMA co-application.
The sigmoid curve fitting the IACh values obtained at the different
concentrations tested had an EC50 of 25 µM (confidence interval,
8–78 µM) and an nH of 1.0 ± 0.3. Thus, pre-application of
DMA followed by its co-application with 10 µM ACh increased
only modestly the percentage of IACh inhibition obtained by
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FIGURE 5 | 2,6-Dimethylaniline effects on IACh decay and time-to-peak. (A) Superimposed IACh recordings evoked by application of 100 µM ACh either alone
(black recoding) or plus 2 mM DMA (green recording) and by re-applying 100 µM ACh alone 7 min after DMA washout (Postcontrol, gray trace overlapping the
control one). Note that all IACh amplitudes have been scaled to the same size to better showing differences on IACh desensitization. Inset shows, at an expanded
temporal scale, the IACh peaks elicited by ACh either alone or co-applied with DMA. (B) Plots showing the percentage of IACh decay obtained at different times (2,
10, and 20 s) after IACh peak. Data were measured from recordings as those shown in (A), by applying 100 µM ACh either alone (Control, filled circles and
continuous black line; Postcontrol, filled triangles and dashed black line) or plus 2 mM DMA (open circles and continuous green line). (C) Column graph showing the
IACh time-to-peak values when applying 100 µM ACh either alone (Control and Postcontrol, empty columns) or together with 2 mM DMA (filled green column). Values
of n and N, given in each column, are common to (B,C); in both panels, asterisks indicate significant differences among groups (p < 0.05, ANOVA and Bonferroni
t-test). (D) Plot displays the DMA dose-dependence of IACh decay hastening. Desensitization values (Dtis) at 2 (orange), 10 (pink) and 20 s (violet) from IACh peaks,
elicited by co-applying 100 µM ACh with 100, 200, 500, or 2000 µM DMA, were expressed as percentage respect to their control Dtis and plotted against the log of
DMA concentration. Each point is the average of 4–12 oocytes from three frogs. Asterisks of different colors indicate significant differences respect to the control
values for the color-coded time (p < 0.05, one sample t-test). Inset shows superimposed recordings evoked by 100 µM ACh either alone or together with 200 µM
DMA; recording colors are as in (A) and IACh amplitudes have also been scaled to the same size.
barely DMA and ACh co-application (53.9 ± 1.9%, n = 28,
N = 13, for direct co-application, versus 65.1 ± 2.4%, n = 15,
N = 8, for pre-application followed by co-application; p < 0.05,
t-test; Figures 7A1,A2,C). Noteworthy, the enhancement of IACh
inhibition by DMA pre-application was stronger when it was later
co-applied with high ACh concentrations, as it would be expected
if DMA pre-application blocked resting nAChRs. Thereby, the
percentage of IACh inhibition by 2 mM DMA and 1 mM ACh
co-application was 28.7 ± 5.7% (n = 4, N = 2) and increased to
90.1± 3.5% (n= 5, N = 3; p< 0.05, t-test) when the same DMA
concentration was pre-applied and then co-applied with 1 mM
ACh (compare recordings of panels Figures 7A1,A2,C).
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 November 2016 | Volume 9 | Article 127
fnmol-09-00127 November 22, 2016 Time: 13:44 # 9
Alberola-Die et al. nAChR Modulation by 2,6-Dimethylaniline
FIGURE 6 | IACh decay hastening elicited by DMA is dependent on ACh
concentration. (A) Superimposed recordings of IAChs elicited by 10 µM (A1)
or 1 mM (A2) ACh either alone (black recordings) or co-applied with 2 mM
DMA (green recordings) in oocytes with the membrane potential held at
+40 mV. IACh decays were fitted to exponential curves (red discontinuous
lines) and the time constant (τ) values for each group were determined. (B).
Column graph of τ values for IACh decays. Data of each column are
mean ± SEM from 4 to 6 oocytes (N = 3). When co-applying DMA and 1 mM
ACh, the IACh decay was best fitted to double exponential curves and the τ
value shown in B corresponds to the fast component. Note that both control
IACh amplitude and desensitization rate increased with ACh concentration (see
black recordings in A1,A2; B, open columns) and mind the presence of
rebound-currents when ACh and DMA were co-applied (green records),
independently of the ACh dose used. Observe that DMA co-application
caused a stronger blocking effect at low (A1) than at high (A2) ACh
concentrations and that DMA enhancement of the rate of IACh decay was
greater for higher ACh doses (compare recordings of A1, A2; B). The asterisk
indicates significant differences between both DMA groups (p < 0,05, t-test),
and the pound sign denotes that this column is truncated, because IAChs
elicited by 10 µM ACh showed almost no desensitization.
Additive Inhibitory Effects of DMA with
DEA
Since DEA and DMA are structurally quite different molecules
and both cause inhibitory effects on nAChRs (see Alberola-
Die et al., 2016), we assessed the effect of co-application of
DMA with DEA in the presence of 10 µM ACh, aiming to
unravel whether or not their inhibitory actions on nAChRs are
additive. Co-application of 10 µM ACh with 70 µM DEA (close
to its IC50) decreased IACh by 47.6 ± 2.0% (Figures 8A1,B).
A similar percentage of IACh blockade was obtained when ACh
(10 µM) was co-applied with 2 mM DMA (53.9 ± 1.9%;
Figures 8A2,B). The IACh inhibition increased significantly when
these same doses of DMA and DEA were co-applied together
with 10 µM ACh (77.7 ± 1.3%; Figures 8A3,B; p < 0.05, t-test).
This enhancement of IACh inhibition by co-application of DEA
and DMA could be due to either syntopic (both molecules
sharing a single binding site) or allotopic (binding to different
loci) interaction of these molecules on the nAChR. Using the
theoretical approach proposed by Jarvis and Thompson (2013) to
discriminate between both interaction models (see Materials and
Methods Eqs. (4) and (5)), we found that IACh inhibition caused
by DEA and DMA co-application properly fitted to the values
predicted by the allotopic model, but were significantly different
to those estimated by the syntopic one (Figure 8B).
A further experimental evidence for allotopic interaction
of DMA and DEA was attained by determining the nAChR
pharmacological profile in the presence of both DMA and
DEA. Thus, nAChR bearing oocytes were challenged with
different ACh concentrations (1 µM–1 mM) in the presence of
1 mM DMA and 30 µM DEA, which are the concentrations
corresponding to their IC30 for nAChR blockade (see Figure 1
and Alberola-Die et al., 2016, respectively). Then, if DMA and
DEA interact with nAChRs at different loci, it should be expected
roughly a 50% decrease in the IACh when applied together
at these doses. Noticeably, the dose-response curve obtained
in the presence of DMA and DEA fairly well-matched the
pharmacological profile of nAChRs in the presence of the whole
lidocaine molecule at its IC50 (Figure 9). Actually, we found
non-significant differences between the values found for the dose-
response curve in the presence of DEA and DMA and those
previously attained in the presence of lidocaine (p > 0.05, t-test;
Alberola-Die et al., 2011). Furthermore, the estimated EC50 value
(65 µM) of nAChRs in the presence of DEA and DMA was
within the confidence interval of the EC50 in the presence of
lidocaine (64–147 µM). Therefore, as it could be expected from
their differences in molecular structure, DEA and DMA act by
different mechanisms and bind to different sites on nAChRs.
Virtual Docking Assays
We have explored the interactions between DMA and the
nAChR, using as template the full structure of Torpedo nAChR
in both closed and open conformations (see Materials and
Methods). We carried out 500 runs for DMA-nAChR interactions
for both the closed and the open states. For the closed state,
we found 60 clusters of interaction sites that differ in less
than 5 Å of root-mean-square-deviation. DMA clusters on
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FIGURE 7 | 2,6-Dimethylaniline effects on ACh concentration-IACh amplitude relationship. (A) IACh recordings evoked by applying, successively, ACh at
increasing concentrations (10, 100 µM, and 1 mM) either alone (black traces) or co-applied with 2 mM DMA either directly (A1, green recordings) or after being
pre-applied for 12 s (A2, red recordings). (B) Averaged ACh concentration-IACh amplitude curves obtained following the experimental protocol shown in (A). Black
filled circles are for ACh alone (n = 10–23, N = 4–5), green open circles for co-application of ACh plus 2 mM DMA (n = 4–5, N = 3) and red open circles when ACh
and DMA co-application was preceded by 12 s of 2 mM DMA pre-application (n = 4–7, N = 2–4). All data were normalized to the maximal IACh elicited by ACh alone
and fitted to the Hill equation (continuous lines). (C) Plot showing the percentage of IACh inhibition at different ACh concentrations when ACh was directly co-applied
with 2 mM DMA (open green circles and solid line; n = 4–28, N = 4–10), or when ACh and 2 mM DMA co-application was preceded by 12 s DMA pre-application
(open red circles; n = 5–15, N = 4–9). Asterisks indicate significant differences (p < 0.05, ANOVA and Bonferroni t-test) respect to the IACh blockade caused by
solely co-applying 10 µM ACh and 2 mM DMA; pound signs indicate significant differences (t-test), for each ACh dose, between the IACh blockade caused by direct
co-application of ACh with DMA and when it was preceded by a 12 s DMA application. The dashed line indicates 50% inhibition. Note the reduction of IACh inhibition
when DMA was co-applied with high ACh concentrations (1 mM) and the strong IACh blockade when DMA was pre-applied before its co-application with high ACh
concentrations.
Frontiers in Molecular Neuroscience | www.frontiersin.org 10 November 2016 | Volume 9 | Article 127
fnmol-09-00127 November 22, 2016 Time: 13:44 # 11
Alberola-Die et al. nAChR Modulation by 2,6-Dimethylaniline
FIGURE 8 | Additive inhibitory effects of DMA and DEA on IACh. (A1–A3) Representative IACh recordings obtained when superfusing the oocyte with 10 µM
ACh either alone (A1–A3; Control, black) or co-applied with 70 µM DEA (A1; + 70 µM DEA, orange), 2 mM DMA (A2; + 2 mM DMA, green) or 70 µM DEA plus
2 mM DMA (A3; + 70 µM DEA + 2 mM DMA, red). (B) Column graph showing the average IACh inhibition elicited by co-application of 10 µM ACh with the different
combinations showed in (A) as indicated below each column. The two right most columns show the values predicted by the allotopic and syntopic models of
interaction (see text for details). The asterisks above the bars indicate significant differences between groups (p < 0.05, t-test; comparisons of DEA + DMA values
with those estimated by each model of inhibition were carried out with one-sample t-test).
the nAChR were mainly located at the TM (52%) and EC
(46%) domains, with only 1 cluster sited at the intracellular
(IC) domain, sited adjacent to the TM region (Figure 10A).
On the TM domain, DMA interacted both at intrasubunit
crevices and at intersubunit interfaces, being these latter ones the
more numerous, involving each single pair of nAChR subunits
(Figures 10B1,B2). Interestingly, we found discernable changes
on DMA binding to the TM domains in the closed and open
states. Thus, in closed nAChRs DMA interacted preferentially
with residues located at intra- and intersubunit spots but not
into the channel pore (Figures 10B1,B2), whereas in the open
state the hotspots for DMA were less numerous at intersubunit
crevices (compare panels B2,C2 of Figure 10) and some appeared
inside the channel pore (Figure 10C1, red circle). Noticeably,
DMA binding sites on nAChR at the TM domain follow a pattern
similar to that found for the entire lidocaine molecule on this
receptor (see Supplementary Figure S1; Alberola-Die et al., 2016).
At the EC domain, DMA bound at several intrasubunit crevices,
mainly located on α1, α2, and β subunits (Figure 10A) and at
the interface of α1-γ, γ-α2, δ-β, and β-α1 subunits. DMA was
not found occupying the orthosteric sites, though there was a
hotspot for DMA at the α1-γ interface relatively close to the
ligand-binding site (Figure 10A).
DISCUSSION
We have studied the effect of DMA, which resembles the
lipophilic aromatic ring of lidocaine, on muscle-type nAChRs,
in order to unravel the structural determinants of the multiple
inhibitory actions that lidocaine has on this receptor. As DEA (an
analog of lidocaine’s hydrophilic moiety), DMA has inhibitory
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FIGURE 9 | Similar pharmacological profile of nAChRs in the presence
of either combined DEA and DMA or lidocaine. (A) IACh recordings
elicited by applying, sequentially, ACh at increasing concentrations (10,
100 µM, and 1 mM) either alone (black traces) or co-applied with 1 mM DMA
and 30 µM DEA (red traces). (B) Averaged ACh concentration-IACh amplitude
curves attained following the experimental protocol shown in (A). Black filled
circles are for ACh alone (n = 4–7, N = 1) and red open circles when ACh
was co-applied with DMA and DEA (same cells than the control curve). All
data were normalized to the maximal IACh elicited by ACh alone and fitted to
Eq. (3). Continuous black and red lines are the fitted curves, labeled as
ControlDEA+DMA and DEA+DMA, respectively. Added to this plot are the
values we reported for the dose-response curves of nAChRs activated by
ACh either alone (gray symbols and discontinuous line; ControlLid) or in the
presence of 70 µM lidocaine (orange circles and discontinuous line; Lid; data
from Alberola-Die et al., 2011). Notice the similarities among both control
curves and between DEA+DMA and lidocaine curves.
actions on nAChRs, but the two molecules differ in blocking
potency, mechanisms of inhibition and binding sites on this
receptor.
The blocking potency for DMA was in the millimolar range
(Figure 1), which is far greater than the IC50 values found for
either lidocaine or DEA (roughly 70 µM; Alberola-Die et al.,
2011, 2016). Since DMA has a low pKa (3.95; Gómez et al.,
1972), most DMA molecules are unprotonated at physiological
pH. In our recording solution (pH 7.0), the concentration of
the uncharged form of lidocaine is roughly one-10th of the total
species of lidocaine and, therefore, the DMA blocking potency
would be roughly two orders of magnitude lower than that
of neutral lidocaine. In consonance with this, using molecular
properties of LAs as predictors of their affinity for nAChRs, Pagán
et al. (2007) found that molecular weight, molecular volume,
surface area and LogP (partition coefficient of the uncharged
form between octanol/aqueous phases) of the hydrophilic portion
of amide LAs (as lidocaine) correlated better with its IC50
than does the hydrophobic portion. Similarly, phenol, which
also resembles the aromatic tail of lidocaine, caused the slow
block of cardiac sodium channels seen with lidocaine, but its
blocking potency was an order of magnitude lower (Zamponi
and French, 1993). By contrast, 2,6-dimethylphenol, which has
a molecular structure more analogous to DMA than just phenol,
blocked either neuronal or skeletal-muscle sodium channels with
a potency similar to that shown by the complete lidocaine
molecule (Haeseler et al., 2002). Noteworthy, besides blocking
voltage-gated sodium channels, 2,6-dimethylphenol potentiates
and/or caused direct activation of GABA-A receptors (Krasowski
et al., 2001; Mohammadi et al., 2001), which is opposite to
the inhibitory effect that the whole lidocaine molecule has on
this LGIC (Hara and Sata, 2007). In the case of DMA, at the
concentrations used in this work, rather than enhancing GABA-A
receptors decreased their activity (roughly 10% with 2 mM DMA)
and, besides, slightly accelerated the GABA-A current decay (see
Supplementary Figure S2).
The nAChR recovery from blockade by DMA was slower
than that caused by either lidocaine or DEA (Alberola-Die et al.,
2011, 2016) and much slower than the recovery from inhibition
by the quaternary-ammonium anticholinesterases BW284c51 or
edrophonium (Olivera-Bravo et al., 2007). This is most likely
because DMA acts deeply into the membrane (note in Figure 10
that most nAChR hotspots for DMA binding were located at
the TM domain in the virtual docking assays), as it happens
with neutral LAs (Pérez-Isidoro et al., 2014), which would
increase its rinsing time. Actually, there are a variety of binding
sites for hydrophobic molecules at the lipid-nAChR interface,
mostly occupied by membrane phospholipids, but uncharged
LAs, and likely DMA, might compete for these intramembranous
binding sites (Mantipragada et al., 2003). In this sense, it should
be pointed out that lidocaine, and likely other amphipathic
molecules, might follow both hydrophobic and hydrophilic
pathways through the membrane to reach their deep binding
sites in the voltage-dependent sodium channels (Hille, 1977), and
something similar would be expected for the nAChR.
2,6-Dimethylaniline caused a voltage-independent blockade
of nAChRs (Figure 3), likely by acting outside the channel pore
on resting nAChRs (see below). Nevertheless, some neutral LAs,
as benzocaine, can block open nAChR channels (Ogden et al.,
1981). Interestingly, we found prominent IACh rebounds after co-
application of ACh and DMA, when DMA began to be rinsed
out (Figures 4 and 6). This IACh rebound might arise if DMA
binds with low affinity into the open channel pore, as it has
been proposed for ACh (Legendre et al., 2000; Liu et al., 2008)
and other fast channel blockers, as TMA or choline (Lape et al.,
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FIGURE 10 | Modeling of DMA binding to nAChR EC- and TM-domains in the open and closed states. (A) Lateral view, in the membrane plane (top
corresponding to the EC side) of nAChR, in the closed state, with bound DMA molecules. Subunits are colored for this and following panels as follows: α1 (blue), α2
(cyan), β (magenta), γ (orange), and δ (green). DMA molecules are colored brown and represented as van der Waals spheres. Notice that DMA binds both at the EC
and TM domains. The red arrow indicates the orthosteric binding site at the α1-γ interface. (B1,C1) Top view (from the synaptic cleft) of nAChR structures in the
closed (B1) and open (C1) states with bound DMA molecules. Note that, when closed, at the EC domain, DMA binds to intrasubunit loci (arrows in B1), mainly
located on α1, α2 and β subunits, whereas at the TM domain DMA preferentially interact with residues located at intersubunit crevices. Also note that DMA binds
within the channel pore only on nAChRs in the open state (red circle in C1). (B2,C2) Expanded top view of nAChR TM domains in the closed (B2) and open (C2)
states with bound DMA. Note that whereas in the closed state DMA binds at all intersubunit assemblies (arrows in B2), in the open state these binding sites were
less favored.
2009). Thus, when DMA concentration decreases by washout,
the channel would be unplugged, at a time when there is yet
enough ACh to keep some nAChRs open. The DMA low-affinity
binding would explain why IACh rebound was only elicited
when DMA concentration was over 500 µM. The larger IACh
rebound found when the cell was challenged with a high ACh
concentration could be due to the presence of a larger remanent
ACh concentration during the washout, which is required for
nAChR activation. Accordingly, virtual docking assays show a
hotspot for DMA binding inside the pore in the open nAChR
conformation (Figure 10C1). Alternatively, IACh rebound could
be due to low affinity binding of DMA to the nAChR TM domain
at intersubunit crevices (Figure 10B2), provided this binding
precludes channel opening by ACh. As shown in Supplementary
Figure S1, the pattern of DMA binding to intersubunit cavities in
the nAChR is very similar to that found for the entire lidocaine
molecule (Supplementary Figure S1; Alberola-Die et al., 2016)
and also for the general anesthetics propofol (Supplementary
Figure S1; Ghosh et al., 2013) and isoflurane (not shown;
Brannigan et al., 2010) on the homologous GLIC receptor, in
the resting state. Interestingly, motions at intersubunit crevices
elicited by propofol on GLIC receptors seem different to those
associated with channel activation, which suggests that propofol
stabilize this receptor in the closed state (Ghosh et al., 2013),
and something similar might occur with DMA and lidocaine on
nAChRs. If this is so, lowering DMA concentration by rinsing
would remove this restriction for nAChR gating and thus IACh
rebound would initiate; however, changes in DMA concentration
at deep membrane loci would probably follow a time course too
slow for keeping nAChR activated by the remaining ACh, which
is required to initiate the IACh rebound.
So far, the amine group of the lidocaine molecule (or its analog
DEA) has been proposed as the single molecular determinant
for the open-channel blockade of nAChRs (Alberola-Die et al.,
2011, 2016). By contrast, the aromatic ring of lidocaine (or
its analog DMA) arises as the structural determinant for the
enhancement of the IACh decay elicited by lidocaine, since this
effect could neither be elicited by DEA, even at concentrations
threefold the IC50 (Alberola-Die et al., 2016), nor by low
concentrations of lidocaine (Alberola-Die et al., 2011). The
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IACh decay enhancement by DMA can be explained by two,
not exclusive, mechanisms: (i) by slow open-channel blockade
of nAChRs, which would account for the IACh rebound at
the beginning of DMA rinsing. However, the fact that for
the same DMA concentration the IACh decay time course
was markedly affected by ACh dose (Figure 6) excludes this
mechanism as the only one responsible for this effect; (ii) by
hastening nAChR desensitization, which would better explain
the differences in the rates of IACh decay found for different
ACh concentrations in the presence of the same dose of DMA.
If this is so, the enhancement of nAChR desensitization can
be evoked by direct ACh and DMA co-application, without
requiring DMA preincubation, in contrast with the enhancement
of muscle nAChRs desensitization by adiphenine, which required
2 min preincubation with this LA to reach the maximum effect
(Spitzmaul et al., 2009).
When DMA was pre-applied to the oocyte before its co-
application with ACh, nAChR blockade markedly increased,
mainly at high ACh doses, which strongly suggests that DMA
blocked closed nAChRs. Furthermore, in competition assays,
DMA decreased the maximum ACh-elicited response, as it would
be expected for a non-competitive blocker, but also shifted
significantly to the right the dose-response curve (Figure 7).
This apparent competitive effect of DMA could be explained by
blockade of resting nAChRs, since it precludes their activation by
the agonist, i.e., it would decrease the total number of nAChRs
available for activation. In concordance with this, virtual docking
assays indicated that DMA binds outside the channel pore in the
resting nAChR, mainly at intersubunit crevices of TM and EC
domains (Figures 10A,B1,B2).
Whereas DMA binding sites at TM segments of nAChRs
where rather similar to those found for lidocaine (Supplementary
Figure S1), they were strikingly different to those reported
for DEA (see Alberola-Die et al., 2016), indicating that DMA
and DEA caused specific actions on nAChRs by acting at
different loci. This result was confirmed by analyzing the additive
inhibitory actions caused by co-application of ACh with DEA
and DMA as compared with co-application of ACh with either
DEA or DMA. As it would be expected from our docking
assays, the increase in the percentage of IACh inhibition was
very close to the value estimated from the allotopic model
of interaction of two blockers on an ion channel (Jarvis and
Thompson, 2013). Therefore, DEA and DMA can simultaneously
occupy their specific binding sites on this receptor, eliciting each
one of these molecules selective effects on nAChRs, and when
DEA and DMA are acting together they reproduce most of
the inhibitory actions elicited by the whole lidocaine molecule,
including the pharmacological profile of nAChRs exposed to
lidocaine (see Figure 9). Thus, these results allow to explain why
when lidocaine is applied at low doses (below IC50) it matched
most DEA blocking actions, but at higher doses, it showed
additional inhibitory effects, mimicking some DMA actions.
CONCLUSION
These results indicate that many amphipathic molecules,
including most LAs, might exert a complex modulating action
on nAChRs by simultaneously acting, with different affinities, at
distinct and even distant binding sites on this receptor and, most
likely, this is also suitable for other LGICs.
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